Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a cold sore virus shrink NF1 skin tumors?

NCT ID NCT07102394

Recruiting now Disease control Sponsor: Johns Hopkins University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early study tests whether a drug called IMLYGIC, made from a modified herpes virus, can be safely injected into painful or disfiguring skin tumors in adults with NF1. Ten participants will receive up to 8 injections over 4 months. The goal is to see if the treatment is tolerable and feasible, not yet to prove it works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
IMLYGIC (talimogene laherparepvec), a modified herpes virus injected directly into tumors
What this could lead to
If it works, this could point toward a new way to shrink or control NF1-related skin tumors without surgery.
What could go wrong
This is a very early Phase 1 trial with only 10 people, so it may not work or could cause side effects like flu-like symptoms or injection-site reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CUTANEOUS NEUROFIBROMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neurofibroma neurofibromatosis neurofibromatosis type 1

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CUTANEOUS NEUROFIBROMA NEUROFIBROMA NEUROFIBROMAS NEUROFIBROMATOSIS NF1 VON RECKLINGHAUSEN DISEASE

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Johns Hopkins University

    RECRUITING

    Baltimore, Maryland, 21287, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.